These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study. Forde I; Chandola T; Raine R; Marmot MG; Kivimaki M Atherosclerosis; 2011 Mar; 215(1):223-8. PubMed ID: 21227420 [TBL] [Abstract][Full Text] [Related]
44. Lipid-lowering drugs and homocysteine. de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885 [No Abstract] [Full Text] [Related]
45. Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. Dotani MI; Morise AP; Haque R; Jain AC; Gupta N; Gibson CM Am J Cardiol; 2003 May; 91(9):1107-9. PubMed ID: 12714156 [No Abstract] [Full Text] [Related]
46. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. Baxter C; Jones R; Corr L BMJ; 1998 Oct; 317(7166):1134-5. PubMed ID: 9784452 [No Abstract] [Full Text] [Related]
47. Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics. Rockson SG Curr Atheroscler Rep; 2000 Mar; 2(2):144-50. PubMed ID: 11122738 [TBL] [Abstract][Full Text] [Related]
48. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective. Kessler JM Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610 [No Abstract] [Full Text] [Related]
49. Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind. Ferner RE BMJ; 1998 Dec; 317(7172):1592. PubMed ID: 9836677 [No Abstract] [Full Text] [Related]
50. [Effect of sulodexide on various metabolic risk factors in diabetic macroangiopathies]. Pierfranceschi DG Farmaco Prat; 1986 Feb; 41(2):67-74. PubMed ID: 3699143 [No Abstract] [Full Text] [Related]
52. Pharmacoeconomics of lipid-lowering drugs. Smith DG Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545 [TBL] [Abstract][Full Text] [Related]
53. [Clinical thinking on the intensive lipid-lowering therapy]. Zhao SP; Chen YQ Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):791-2. PubMed ID: 22321223 [No Abstract] [Full Text] [Related]
54. Lipid-lowering therapy for the primary prevention of coronary heart disease. Gotto AM J Am Coll Cardiol; 1999 Jun; 33(7):2078-82. PubMed ID: 10362217 [No Abstract] [Full Text] [Related]
55. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA; BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912 [No Abstract] [Full Text] [Related]
56. The use of statins: a case of misleading priorities? Freemantle N; Barbour R; Johnson R; Marchment M; Kennedy A BMJ; 1997 Oct; 315(7112):826-8. PubMed ID: 9353492 [No Abstract] [Full Text] [Related]
57. Use of statins. Sheffield table is useful. Ramsay LE; Wallis EJ; Haq IU; Williamson R; Yeo WW; Jackson PR BMJ; 1998 Aug; 317(7156):473-4. PubMed ID: 9703541 [No Abstract] [Full Text] [Related]
58. Controversies in hyperlipidaemia: issues resolved? Cramb R Br J Hosp Med; 1996 Dec 11-1997 Jan 14; 56(11):566-7. PubMed ID: 8982480 [No Abstract] [Full Text] [Related]
59. Evaluating the cost-effectiveness of statins. Hay JW J Manag Care Pharm; 2004; 10(1):79-81. PubMed ID: 14720107 [No Abstract] [Full Text] [Related]
60. The SHARP trial: lessons learnt; answers and more questions! Turagam M; Velagapudi P Int J Cardiol; 2012 Apr; 156(1):e6. PubMed ID: 21849215 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]